AVEO Oncology AVEO and Astellas Pharma today
announced that the U.S. Food and Drug Administration (FDA) has accepted
for filing the New Drug Application (NDA) for tivozanib with the
proposed indication for the treatment of patients with advanced renal
cell carcinoma (RCC). Tivozanib is an investigational medicine and is
not currently approved in any country. According to the timelines
established by the Prescription Drug User Fee Act (PDUFA), the review of
the NDA is expected to be complete by July 28, 2013.
The NDA includes results of the global Phase 3 TIVO-1 (TIvozanib
Versus SOrafenib
in 1st line Advanced RCC) trial, a
randomized superiority-designed pivotal trial evaluating the efficacy
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in